Safety Data Timelines for Pregnant Individuals With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy-Reference-Cited by-同舟云学术

Safety Data Timelines for Pregnant Individuals With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy

Published:2024-05-06 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Short William R¹^ORCID,Zimmerman Matty M²,Mohamed Ola¹,Mofenson Lynne M³

Affiliation:

1. Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania , USA

2. Department of Pharmacy, Penn Presbyterian Medical Center , Philadelphia, Pennsylvania , USA

3. Elizabeth Glaser Pediatric AIDS Foundation , Washington, DC , USA

Abstract

Abstract Antiretrovirals are often approved by the Food and Drug Administration without sufficient safety data regarding their use in pregnancy. To quantify this delay, we calculated the interval from the approval date to their inclusion in the Antiretroviral Pregnancy Registry prospective analysis (≥200 first-trimester exposures); the median delay was 6 years.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae249/58197980/ciae249.pdf

Reference16 articles.

1. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception;Mandelbrot;Clin Infect Dis,2015

2. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk;Thorpe;Pharmacoepidemiol Drug Saf,2013

3. Advancing the inclusion of underrepresented women in clinical research;Bierer;Cell Rep Med,2022

4. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents);Brent;Pediatrics,2004